The osteoblastic niche in the context of multiple myeloma

Annals of the New York Academy of Sciences

Volumn 1335, Issue 1, 2015, Pages 45-62

  Toscani, Denise ^a   Bolzoni, Marina ^a   Accardi, Fabrizio ^a   Aversa, Franco ^a   Giuliani, Nicola ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Bone disease; Myeloma; Osteoblast; Osteocyte; Wnt signaling

Indexed keywords

ANIMAL; CELL DIFFERENTIATION; HUMAN; METABOLISM; MULTIPLE MYELOMA; OSTEOBLAST; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; SIGNAL TRANSDUCTION;

EID: 84920505400     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12578     Document Type: Review

References (154)

1. Morrison, S.J. et al. 2014. The bone marrow niche for hematopoietic stem cells. Nature 505: 327-334.
2. Wang, L.D. et al. 2011. Dynamic niches in the origination and differentiation of hematopoietic stem cells. Nat. Rev. Mol. Cell Biol. 12: 643-655.
3. Zhang, J. et al. 2003. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425: 836-841.
4. Bianco, P. 2011. Bone and the hematopoietic niche: a tale of two stem cells. Blood 117: 5281-5288.
5. Baron, R. et al. 2013. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19: 179-192.
6. Tamai, K. et al. 2000. LDL-receptor-related proteins in Wnt signal transduction. Nature 407: 530-535.
7. Behrens, J. et al. 1996. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 382: 638-642.
8. Funayama, N. et al. 1995. Embryonic axis induction by the armadillo repeat domain of β-catenin: evidence for intracellular signaling. J. Cell Biol. 128: 959-968.
9. Noordermeer, J. et al. 1994 Dishevelled and armadillo act in the wingless signalling pathway in Drosophila. Nature. 367: 80-83.
10. Aberle, H. et al. 1997. β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16: 3797-3804.
11. Bhanot, P. et al. 1996. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature. 382: 225-230.
12. Mao, J. et al. 2001. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell 7: 801-809.
13. Nemeth, M.J. et al. 2007. Regulation of hematopoiesis and the hematopoietic stem cell niche by Wnt signaling pathways. Cell Res. 17: 746-758.
14. Cain, C.J. et al. 2013. Hematopoietic stem cell fate decisions are regulated by Wnt antagonists: comparisons and current controversies. Exp. Hematol. 41: 3-16.
15. Nemeth, M.J. et al. 2009. β-Catenin expression in the bone marrow microenvironment is required for long-term maintenance of primitive hematopoietic cells. Stem Cells 27: 1109-1119.
16. Reja, T. et al. 2003. A role of Wnt signaling in self-renewal of hematopoietic stem cells. Nature 423: 409-414.
17. Gómez-Orte, E. et al. 2013 Multiple functions of the noncanonical Wnt pathway. Trends Genet. 29: 545-553.
18. Buckley, S.M. et al. 2011. Maintenance of HSC by Wnt5a secreting AGM-derived stromal cell line. Exp. Hematol. 39: 114-123.
19. Louis, I. et al. 2008. The signaling protein Wnt4 enhances thymopoiesis and expands multipotent hematopoietic progenitors through beta-catenin independent signaling. Immunity 29: 57-67.
20. Vijayaragavan, K. et al. 2009. Noncanonical Wnt signaling orchestrates early developmental events toward hematopoietic cell fate form human embryonic stem cells. Cell Stem Cell 4: 248-262.
21. Kim, D.J. et al. 2008. Differential expression of the Wnt and Frizzled genes in Flk1+ cells derived from mouse ES cells. Cell Biochem. Funct. 26: 24-32.
22. Renstrom, J. et al. 2009. Secreted frizzled-related protein 1 extrinsically regulated cycling activity and maintenance of hematopoietic stem cells. Cell Stem Cell 5: 157-167.
23. Nakajima, H. et al. 2009. Wnt modulators, SFRP-1, and SFRP-2 are expressed in osteoblasts and differentially regulate hematopoietic stem cells. Biochem. Biophys. Res. Commun. 390: 65-70.
24. Schaniel, C. et al. 2011. Wnt-inhibitory factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cell. Blood. 118: 2420-2429.
25. Guruharsha, K.G. et al. 2012. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat. Rev. Genet. 13: 654-666.
26. Karanu, F.N. et al. 2000. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J. Exp. Med. 192: 1365-1372.
27. Weber, J.M. et al. 2010. Notch signaling and the bone marrow hematopoietic stem cell niche. Bone 46: 281-285.
28. Stier, S. et al. 2002. Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood 99: 2369-2378.
29. Bonewald, L.F. et al. 2011. The amazing osteocytes. J. Bone Miner. Res. 26: 229-238.
30. Marotti, G. et al. 1995. Quantitative evaluation on osteocytes canalicular density in human secondary osteons. Bone. 16: 125-128.
31. Qin, L. et al. 2005. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol. Metab. 15: 60-65.
32. Ono, N. et al. 2012. Constitutively active PTH/PTHrP receptor specifically expressed in osteoblasts enhances bone formation induced by bone ablation. J. Cell Phys. 227: 408-415.
33. Calvi, L.M. et al. 2003. Osteoblastic cells regulate the hematopoietic stem cell niche. Nature 425: 841-846.
34. Fulzele, K. et al. 2013. Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling. Blood 121: 930-939.
35. Winkler, I.G. et al. 2010. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 116: 375-385.
36. Spencer, J.A. et al. 2014. Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature 508: 269-273.
37. Tabuko, K. et al. 2010. Regulation of the HIF1α level is essential for hematopoietic stem cells. Stem Cell 7: 391-402.
38. Simon, M.C. et al. 2006. Coming up for air. HIF-1 and mitochondrial oxygen consumption. Cell Metab. 3: 150-151.
39. Gerber, H.P. et al. 2002. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417: 954-958.
40. Franceschi, R.T. et al. 2007. Transcriptional regulation of osteoblasts. Ann. N.Y. Acad. Sci. 1116:196-207.
41. Deng, Z.L. et al. 2008. Regulation of osteogenic differentiation during skeletal development. Front. Biosci. 1: 2001-2021.
42. Boyden, L.M. et al. 2002. High bone density due to a mutation in LDL-receptorrelated protein 5. N. Engl. J. Med. 346: 1513-1521.
43. Gong, Y. et al. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107: 513-523.
44. Ai, M. et al. 2005. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol. Cell Biol. 25: 4946-4955.
45. de Boer, J. et al. 2004. Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 34: 818-826.
46. Boland, G.M. et al. 2004. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J. Cell Biochem. 93: 1210-1230.
47. Baksh, D. et al. 2007. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J. Cell Biochem. 101: 1109-1124.
48. Baksh, D. et al. 2007. Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J. Cell Physiol. 212: 817-826.
49. Li, X. et al. 2005. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat. Genet. 37: 945-952.
50. Van der Horst, G. et al. 2005. Downregulation of Wnt signaling by increased expression of Dickkopf-1 and -2 is a prerequisite for late-stage osteoblast differentiation of KS483 cells. J. Bone Miner. Res. 20: 1867-1877.
51. Vaes, B.L. et al. 2005. Microarray analysis reveals expression regulation of Wnt antagonists in differentiating osteoblasts. Bone 36: 803-811.
52. Chang, J. et al. 2007. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J. Biol. Chem. 282: 30938-30948.
53. Liu, Y. et al. 2008. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J. Cell Biochem. 105: 497-502.
54. Liu, Y. et al. 2007. Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3(β) phosphorylation and promotes osteoblast differentiation and bone formation. Mol. Endocrinol. 21: 3050-3061.
55. Ducy, P. et al. 1997. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 89: 747-754.
56. Franceschi, R.T. et al. 2003. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J. Cell Biochem. 88: 446-454.
57. Liu, W. et al. 2001. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell Biol. 155: 157-166.
58. Shui, C. et al. 2003. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J. Bone Miner. Res. 18: 213-221.
59. Chen, J., 2014. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One 9: e85161.
60. Xiao, G. et al. 2000. MAPK pathways activate and phosphorylate the osteoblastspecific transcription factor, Cbfa1. J. Biol. Chem. 275: 4453-4459.
61. Giuliani, N. et al. 2007. Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma. Leuk. Lymphoma 48: 2323-2329.
62. Giuliani, N. et al. 2009. Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets. Exp. Hematol. 37: 879-886.
63. Giuliani, N. et al. 2006 Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 108: 3992-3996.
64. Roodman, G.D. et al. 2011 Osteoblast function in myeloma. Bone 48: 135-140.
65. Yaccoby, S. et al. 2010. Osteoblastogenesis and tumor growth in myeloma. Leuk. Lymphoma 51: 213-220.
66. Pennisi, A. et al. 2010. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One 5: e15233.
67. Roodman, G.D. et al. 2008. Bone building with bortezomib. J. Clin. Invest. 118: 462-464.
68. Giuliani, N. et al. 2007. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110: 334-338.
69. Chen, Z. et al. 2014. Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123: 2204-2208.
70. Giuliani, N. et al. 2005. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106: 2472-2483.
71. Garayoa, M. et al. 2009. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 23: 1515-1527.
72. Gainor, B.J. et al. 1983. Fracture healing in metastatic bone disease. Clin. Orthop. Relat. Res. 178: 297-302.
73. Giuliani, N. et al. 2010. Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. Leukemia 24: 1368-1370.
74. Reagan, M.R. et al. 2014. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood DOI: 10.1182/blood-2014-02-558007.
75. Lokhorst, H. M. et al. 1994. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood 84: 2269-2277.
76. Wallace, S.R. et al. 2001. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 91: 1219-1230.
77. Li, B. et al. 2010. Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients. Arch. Med. Res. 41: 623-633.
78. Corre, J. et al. 2007. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21: 1079-1088.
79. Arnulf, B. et al. 2007. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21: 158-163.
80. Silvestris, F. et al. 2007. Myeloma bone disease: pathogenetic mechanisms and clinical assessment. Leuk. Res. 31: 129-138.
81. Wang, J. et al. 2014. Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood 124: 555-566.
82. Kassen, D. et al. 2014. The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma. Br. J. Haematol. 167: 194-206.
83. Yaccoby, S. et al. 2006. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91: 192-199.
84. Roccaro, A.M. et al. 2013. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 123: 1542-1555.
85. Hu, W. et al. 2012. miR-142-3p promotes osteoblast differentiation by modulating Wnt signaling. Mol. Med. Rep. 2012: 1207.
86. Wu, T. et al. 2012. miR-155 modulates TNF-α-inhibited osteogenic differentiation by targeting SOCS1 expression. Bone 51: 498-505.
87. Kim, K.M. et al. 2012. miR-182 is a negative regulator of osteoblast proliferation, differentiation, and skeletogenesis through targeting FoxO1. J. Bone Miner. Res. 27: 1669-1679.
88. Huang, S. et al. 2012. Upregolation of miR-22 promotes osteogenic differentiation and inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells by repressing HDAC6 protein expression. Stem Cell Dev. 21: 2531-2540.
89. Xu, S. et al. 2013. Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS One 11: e79752.
90. Tian, E. et al. 2003. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349: 2483-2494.
91. Giuliani, N. et al. 2007. Production of wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 67: 7665-7674.
92. Oshima, T. et al. 2005. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106: 3160-3165.
93. Edwards, C.M. et al. 2008. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842.
94. Qiang, Y.W. et al. 2008. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112: 374-381.
95. Fulciniti, M. et al. 2009. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114: 371-379.
96. Yaccoby, S. et al. 2007. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106-2111.
97. Bolzoni, M. et al. 2013. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. Leukemia 27: 451-463.
98. Koga, T. et al. 2005. NFAT and Osterix cooperatively regulate bone formation. Nat. Med. 11: 880-885.
99. Penolazzi, L. et al. 2011. Transcription factor decoy against NFATc1 in human primary osteoblasts. Int. J. Mol. Med. 28: 199-206.
100. Mori, Y. et al. 2004. Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104: 2149-2154.
101. Hjorth-Hansen, H. et al. 1999. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J. Bone Miner. Res. 14: 256-263.
102. Ely, S.A. et al. 2002. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gamyelomaopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am. J. Pathol. 160: 1293-1299.
103. Weitzmann, M.N. et al. 2002. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J. Clin. Invest. 110: 1643-1650.
104. Giuliani, N. et al. 2002. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100: 4615-4621.
105. Standal, T. et al. 2007. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109: 3024-3030.
106. Edwards, C.M. et al. 2008 The pathogenesis of the bone disease of multiple myeloma. Bone 42: 1007-1013.
107. Hong, J.H. et al. 2005. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309: 1074-1078.
108. + mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev. 16: 921-930.
109. Krishnan, V. et al. 2003. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol. Endocrinol. 17: 423-435.
110. Jilka, R.L. et al. 2007 Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40: 1434-1446.
111. Zhao, Z. et al. 2005. Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol. Ther. 12: 247-253.
112. Colombo, M. et al. 2013. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia 27: 1009-1018.
113. Mirandola, L. et al. 2013. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia 27: 1558-1566.
114. Xu, S. et al. 2012. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia 26: 2546-2549.
115. Evans, C.E. et al. 1992. Myeloma affects both the growth and function of human osteoblast-like cells. Clin. Exp. Metast. 10: 33-38.
116. Silvestris, F. et al. 2004. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br. J. Haematol. 126: 475-486.
117. Silvestris, F. et al. 2003. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br. J. Haematol. 122: 39-52.
118. Tinhofer, I. et al. 2006. A role of TRAIL in killing osteoblasts by myeloma cells. FASEB J. 20: 759-761.
119. Shipman, C.M. et al. 2003. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63: 912-916.
120. Palumbo, C. et al. 1990. Morphological study of intercellular junctions during osteocytes differentiation. Bone 11: 401-406.
121. Tatsumi, S. et al. 2007. Targeted ablation of osteocytes induce osteoporosis with defective mechanotransduction. Cell Metab. 5: 464-475.
122. Van Bezooijen, R.L. et al. 2005. SOST/-sclerostin, an osteocytes-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 16: 319-327.
123. Kamiya, N. et al. 2008. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Development 135: 3801-3811.
124. Weinstein, R.S. et al. 2000. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J. Clin. Endocrinol. Metab. 85: 2907-2912.
125. Tomkinson, A. et al. 1997. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J. Clin. Endocrinol. Metab. 82: 3128-3135.
126. Emerton, K.B. et al. 2010. Osteocyte apoptosis and control of bone resorption following ovariectomy in mice. Bone 46: 577-583.
127. Giuliani, N. et al. 2012. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 126: 1391-1401.
128. Srinivas, V. et al. 2009. Autophagy in mineralizing tissues. Cell Cycle 8: 391-393.
129. Yang, Z. et al. 2009. An overview of the molecular mechanism of autophagy. Curr. Top. Microbiol. Immunol. 335: 1-32.
130. Gurusamy, N. et al. 2009. Is autophagy a double-edged sword for the heart? Acta Physiol. Hung. 96: 267-276.
131. Tsujimoto, Y. et al. 2005. Another way to die: autophagic programmed cell death. Cell Death Differ. 12: 1528-1534.
132. Xuechun, X. et al. 2010. Glucocorticoid-induced autophagy in osteocytes. J. Bone Miner. Res. 25: 2479-2488.
133. Canalis, E. et al. 2002. Mechanisms of glucocorticoid action in bone. Ann. N.Y. Acad. Sci. 966: 73-81.
134. Van Staa, T.P. et al. 2000. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15: 993-1000.
135. Lane, N.E. et al. 2006. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocytes lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J. Bone Miner. Res. 21: 466-476.
136. Maiuri, M.C. et al. 2007. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. 8: 741-752.
137. Colla, S. et al. 2010. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 24: 1967-1970.
138. Vacca, A. et al. 1999. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 93: 3064-3073.
139. Storti, P. et al. 2013. Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia 27: 1697-1706.
140. Colla, S. et al. 2007. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 109: 4470-4477.
141. Mukherjee, S. et al. 2008. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J. Clin. Invest. 118: 491-504.
142. Mohty, M. et al. 2014. The effects of bortezomib on bone disease in patients with multiple myeloma. Cancer 120: 618-623.
143. Li, Y. et al. 2014. Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro. Leuk. Res. 38: 970-976.
144. Garcia-Gomez, A. et al. 2014. Preclinical activity of the oral proteasome inhibitor MLN9708 in myeloma bone disease. Clin. Cancer Res. 20: 1542-1554.
145. Heath, D.J. et al. 2009. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner. Res. 24: 425-436.
146. Padhi, D. et al. 2011. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26: 19-26.
147. McClung, M.R. et al. 2014. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370: 412-420.
148. Blick, S.K. et al. 2008. Teriparatide: a review of its use in osteoporosis. Drugs 68: 2709-2737.
149. Zangari, M. et al. 2014. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone 61: 39-43.
150. Andersson, E.R. et al. 2014. Therapeutic modulation of Notch signalling-are we there yet? Nat. Rev. Drug Discov. 13: 357-378.
151. Ramakrishnan, V. et al. 2012. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia 26: 340-348.
152. de la Puente, P. et al. 2014. Molecularly targeted therapies in multiple myeloma. Leuk. Res. Treat.: 976567.
153. Greenberger, L.M. et al. 2008. A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7: 3598-3608.
154. Lee, K. et al. 2011. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor. Arch. Pharm. Res. 34: 1583-1585.